224 related articles for article (PubMed ID: 32533623)
21. Pre-trilostane and three-hour post-trilostane cortisol to monitor trilostane therapy in dogs.
Macfarlane L; Parkin T; Ramsey I
Vet Rec; 2016 Dec; 179(23):597. PubMed ID: 27803375
[TBL] [Abstract][Full Text] [Related]
22. Study of the effects of once daily doses of trilostane on cortisol concentrations and responsiveness to adrenocorticotrophic hormone in hyperadrenocorticoid dogs.
Bell R; Neiger R; McGrotty Y; Ramsey IK
Vet Rec; 2006 Aug; 159(9):277-81. PubMed ID: 16946310
[TBL] [Abstract][Full Text] [Related]
23. Comparison of methods to monitor dogs with hypercortisolism treated with trilostane.
Golinelli S; de Marco V; Leal RO; Barbarossa A; Aniballi C; Maietti E; Tardo AM; Galac S; Fracassi F
J Vet Intern Med; 2021 Nov; 35(6):2616-2627. PubMed ID: 34672018
[TBL] [Abstract][Full Text] [Related]
24. Effect of trilostane on serum concentrations of aldosterone, cortisol, and potassium in dogs with pituitary-dependent hyperadrenocorticism.
Wenger M; Sieber-Ruckstuhl NS; Müller C; Reusch CE
Am J Vet Res; 2004 Sep; 65(9):1245-50. PubMed ID: 15478772
[TBL] [Abstract][Full Text] [Related]
25. Carbenoxolone Disodium Treatment for Canine Pituitary-Dependent Hyperadrenocorticism.
Teshima T; Matsumoto H; Okusa T; Uchiyama R; Koyama H
PLoS One; 2016; 11(11):e0166267. PubMed ID: 27824928
[TBL] [Abstract][Full Text] [Related]
26. Comparison of Survival Times for Dogs with Pituitary-Dependent Hyperadrenocorticism in a Primary-Care Hospital: Treated with Trilostane versus Untreated.
Nagata N; Kojima K; Yuki M
J Vet Intern Med; 2017 Jan; 31(1):22-28. PubMed ID: 27906457
[TBL] [Abstract][Full Text] [Related]
27. Prognostic factors for survival in dogs with pituitary-dependent hypercortisolism treated with trilostane.
Fracassi F; Corradini S; Floriano D; Boari A; Aste G; Pietra M; Bergamini PF; Dondi F
Vet Rec; 2015 Jan; 176(2):49. PubMed ID: 25170036
[TBL] [Abstract][Full Text] [Related]
28. Use of the urine cortisol-to-creatinine ratio for monitoring dogs with pituitary-dependent hyperadrenocorticism during induction treatment with mitotane (o,p'-DDD).
Randolph JF; Toomey J; Center SA; Scarlett JM; Reimers T; Graham P; Nachreiner RF
Am J Vet Res; 1998 Mar; 59(3):258-61. PubMed ID: 9522940
[TBL] [Abstract][Full Text] [Related]
29. Trilostane treatment in dogs with pituitary-dependent hyperadrenocorticism.
Braddock JA; Church DB; Robertson ID; Watson AD
Aust Vet J; 2003 Oct; 81(10):600-7. PubMed ID: 15080470
[TBL] [Abstract][Full Text] [Related]
30. The effect of 1 year of trilostane treatment on peripheral lymphocyte subsets in dogs with pituitary-dependent hyperadrenocorticism.
Oda H; Mori A; Shono S; Onozawa E; Sako T
J Vet Med Sci; 2016 Jun; 78(5):851-4. PubMed ID: 26782012
[TBL] [Abstract][Full Text] [Related]
31. Association between ACTH stimulation test results and clinical signs in dogs with hyperadrenocorticism treated with trilostane.
Wehner A; Glöckner S; Weiss B; Ballhausen D; Stockhaus C; Zablotski Y; Hartmann K
Vet J; 2021 Oct; 276():105740. PubMed ID: 34416401
[TBL] [Abstract][Full Text] [Related]
32. Lack of association between clinical signs and laboratory parameters in dogs with hyperadrenocorticism before and during trilostane treatment.
Boretti FS; Holzthüm J; Reusch CE; Sieber-Ruckstuhl NS
Schweiz Arch Tierheilkd; 2016 Sep; 158(9):631-638. PubMed ID: 27655162
[TBL] [Abstract][Full Text] [Related]
33. Serum cholecystokinin concentrations in dogs with naturally acquired pituitary-dependent hyperadrenocorticism.
Noh S; Kim HS; Chang J; Kang JH; Chang D; Yang MP
Am J Vet Res; 2016 Oct; 77(10):1101-7. PubMed ID: 27668581
[TBL] [Abstract][Full Text] [Related]
34. Long-term efficacy of trilostane administered twice daily in dogs with pituitary-dependent hyperadrenocorticism.
Alenza DP; Arenas C; Lopez ML; Melian C
J Am Anim Hosp Assoc; 2006; 42(4):269-76. PubMed ID: 16822765
[TBL] [Abstract][Full Text] [Related]
35. Comparison of 2 Doses for ACTH Stimulation Testing in Dogs Suspected of or Treated for Hyperadrenocorticism.
Aldridge C; Behrend EN; Kemppainen RJ; Lee-Fowler TM; Martin LG; Ward CR; Bruyette D; Pannu J; Gaillard P; Lee HP
J Vet Intern Med; 2016 Sep; 30(5):1637-1641. PubMed ID: 27425787
[TBL] [Abstract][Full Text] [Related]
36. Effect of Intravenous or Perivascular Injection of Synthetic Adrenocorticotropic Hormone on Stimulation Test Results in Dogs.
Johnson CM; Kass PH; Cohen TA; Feldman EC
J Vet Intern Med; 2017 May; 31(3):730-733. PubMed ID: 28407319
[TBL] [Abstract][Full Text] [Related]
37. Trilostane dose versus body weight in the treatment of naturally occurring pituitary-dependent hyperadrenocorticism in dogs.
Feldman EC; Kass PH
J Vet Intern Med; 2012; 26(4):1078-80. PubMed ID: 22708554
[TBL] [Abstract][Full Text] [Related]
38. Trilostane treatment of 78 dogs with pituitary-dependent hyperadrenocorticism.
Neiger R; Ramsey I; O'Connor J; Hurley KJ; Mooney CT
Vet Rec; 2002 Jun; 150(26):799-804. PubMed ID: 12120922
[TBL] [Abstract][Full Text] [Related]
39. Treatment of canine Alopecia X with trilostane.
Cerundolo R; Lloyd DH; Persechino A; Evans H; Cauvin A
Vet Dermatol; 2004 Oct; 15(5):285-93. PubMed ID: 15500480
[TBL] [Abstract][Full Text] [Related]
40. TRH-induced secretion of adrenocorticotropin and cortisol in dogs with pituitary-dependent hypercortisolism.
Pijnacker T; Knies M; Galac S; Sanders K; Mol JA; Kooistra HS
Vet Q; 2018 Dec; 38(1):72-78. PubMed ID: 30362899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
